approxim
one
billion
case
influenza
occur
around
world
everi
year
despit
avail
effect
vaccin
associ
estim
death
million
hospit
annual
impos
signific
econom
burden
even
develop
countri
epidem
pandem
set
rapid
differenti
influenza
influenzalik
ill
ili
essenti
infect
control
patient
manag
howev
rel
nonspecif
present
mean
influenza
reliabl
distinguish
ili
present
autumn
winter
season
current
avail
diagnost
system
lack
sensit
specif
requir
effici
differenti
ili
health
facil
triag
station
varieti
differ
diagnost
test
avail
detect
common
respiratori
virus
still
unmet
need
rapid
sensit
accur
diagnosi
commonli
use
convent
method
viru
cultur
serolog
test
antigen
detect
direct
immunofluoresc
reason
sensit
rel
complex
labourintens
gener
slow
clinic
relev
rapid
antigen
pointofcar
test
wide
avail
influenza
rsv
take
minut
perform
sensit
lower
nucleic
acid
test
nat
predict
oseltamivir
resist
occur
within
outbreak
certain
influenza
subtyp
presenc
sever
cocircul
influenza
virus
differ
epidem
potenti
also
make
subtyp
particularli
valuabl
gener
avail
rapid
method
use
recent
describ
mtpcr
method
develop
quantit
assay
import
caus
ili
identif
influenza
subtyp
evalu
perform
two
clinic
laboratori
combin
nose
throat
swab
collect
centr
infecti
diseas
microbiolog
cidm
westmead
hospit
sydney
southern
hemispher
winter
use
initi
assay
valid
centr
immunolog
st
vincent
hospit
sydney
cfi
gammairradi
mdcktissu
cultur
extract
known
amount
indonesian
indo
indonesia
clade
vietnames
hn
vietnam
clade
strain
influenza
viru
provid
australiawid
control
templat
use
along
local
cultiv
tissu
cultur
extract
anew
influenza
viru
influenza
b
viru
perform
use
fluoresceinconjug
monoclon
antibodi
chemicon
intern
temecula
ca
usa
influenza
b
rsv
adenovirus
acetonefix
smear
materi
respiratori
tract
specimen
indic
previous
describ
nucleic
acid
extract
clinic
specimen
tissu
cultur
use
high
pure
viral
rna
extract
kit
roch
diagnost
gmbh
mannheim
germani
elut
sampl
elut
buffer
neg
control
extract
everi
batch
mtpcr
primer
design
modifi
version
primer
softwar
base
align
avail
sequenc
deposit
genbank
tabl
cdna
amplicon
obtain
known
viru
isol
cidm
clone
pgemt
promega
posit
control
nest
revers
transcriptas
polymeras
chain
reaction
rtpcr
use
detect
influenza
b
respiratori
virus
previous
describ
dna
sequenc
pcr
amplicon
determin
need
clone
pgemt
dye
primer
sequenc
promega
compar
known
sequenc
use
eclustalw
angi
melt
temperatur
rang
either
side
predict
tm
deem
accept
melt
curv
normal
sigmoid
verif
corrects
discret
amplicon
deriv
step
mtpcr
assay
perform
use
bioanalyz
dna
separ
chip
agil
technolog
forest
hill
victoria
australia
previous
describ
twostep
assay
use
nest
primer
pair
first
step
involv
highli
multiplex
reaction
preamplifi
multipl
target
typic
cycl
aliquot
individu
reaction
tube
contain
nest
specif
pcr
primer
templat
second
step
reaction
perform
use
liquid
handl
robot
system
provid
ausdiagnost
pti
ltd
sydney
australia
primer
artifici
intern
control
sequenc
shown
due
commerci
confidenti
agreement
ausdiagnost
pti
ltd
target
region
specifi
tabl
exampl
sequenc
intern
control
contriv
sequenc
appear
natur
base
pair
redund
specifi
primer
use
lyophil
primer
reagent
kit
prepar
cfi
sent
cidm
institut
medic
veterinari
scienc
imv
royal
adelaid
hospit
adelaid
test
clinic
sampl
collect
routin
investig
ili
outbreak
sporad
infect
two
referr
centr
mtpcr
perform
strip
tube
contain
step
multiplex
primer
place
thermal
cycler
along
genedisc
contain
lyophilis
step
reagent
oil
cover
pcr
reaction
robot
deck
sampl
directli
ad
strip
tube
thermal
cycler
softwar
templat
reaction
select
oper
perform
step
multiplex
preamplif
dilut
aliquot
step
reaction
tube
genedisc
perform
automat
genedisc
hermet
seal
heatseal
step
amplif
carri
rotorgen
thermal
cycler
end
step
presenc
absenc
target
automat
call
use
softwar
routin
ausdiagnost
pti
ltd
compar
melt
temperatur
product
expect
valu
check
puriti
quantiti
predetermin
threshold
valu
manual
verifi
cycl
threshold
ct
number
cycl
takeoff
point
amplif
curv
see
figur
quantit
comparison
intern
control
assign
arbitrari
valu
chosen
lowest
concentr
target
detect
valu
concentr
final
step
product
express
rel
control
previous
describ
assay
develop
detect
influenza
virus
b
infa
infb
respiratori
syncyti
viru
rsv
rhinoviru
rv
human
parainfluenza
viru
type
identifi
influenza
haemagglutinin
gene
type
within
multiplex
tandem
pcr
mtpcr
assay
profil
use
sequenc
avail
strain
laboratori
lodg
genbank
includ
refer
sequenc
list
tabl
multiplex
assay
gener
configur
divid
neatli
number
posit
avail
standard
step
templat
cycler
empti
well
remain
primer
target
influenza
haemagglutinin
gene
influenza
profil
replac
primer
target
nucleoprotein
gene
human
parainfluenza
viru
type
anoth
assay
profil
data
deidentifi
addit
test
laboratori
sampl
approv
qualiti
assur
activ
sydney
west
area
health
servic
human
research
ethic
committe
thirtynin
viral
cellcultur
extract
store
clinic
isol
includ
isol
identifi
infa
n
infb
n
rsv
n
rv
n
along
undifferenti
picornaviru
n
one
coronaviru
coronaviru
hmpv
enteroviru
adenoviru
type
adenoviru
type
test
use
influenza
profil
infa
infb
rv
rsv
blind
fashion
lab
assay
develop
cfi
signal
normalis
intern
control
valu
arbitrari
unit
infb
rsv
detect
known
control
sampl
posit
signal
observ
sampl
wateronli
control
triplic
assay
data
shown
detect
infa
sensit
specif
exampl
step
cycl
melt
curv
shown
figur
preamplif
cycl
step
step
cycl
melt
curv
multiplex
assay
gene
target
specif
influenza
influenza
b
respiratori
syncyti
viru
rsv
rhinoviru
rv
human
parainfluenza
viru
figur
panel
right
left
colour
scheme
correspond
black
line
intern
control
infa
specif
examin
infa
subtyp
detect
test
serial
dilut
irradi
whole
extract
cell
cultur
supernat
refer
strain
indonesian
vietnames
strain
influenza
profil
tabl
dilut
sampl
contain
copi
rna
one
haemagglutinin
type
gave
greater
fluoresc
signal
anoth
normal
intern
control
deem
correct
result
due
limit
avail
control
sampl
eluat
equival
concentr
viru
extract
effici
use
analysi
recommend
extract
nasal
pharyng
sampl
assay
tabl
perform
serial
tenfold
dilut
whole
cell
cultur
extract
yield
specif
signal
normalis
unit
infa
similarli
serial
dilut
whole
cell
cultur
extract
yield
specif
signal
infa
low
crossreact
least
dilut
sampl
differenti
eg
signal
obtain
highest
dilut
whole
cell
cultur
extract
infa
detect
low
level
lowlevel
crossreact
less
rel
observ
tabl
concentr
viru
sampl
shown
parenthes
tabl
previous
determin
detect
level
low
singl
copi
origin
sampl
strain
next
test
set
assay
influenza
profil
cidm
ul
nucleic
acid
extract
obtain
fortyf
clinic
specimen
retriev
storag
deg
c
previous
collect
investig
influenza
institut
sever
subject
take
antivir
agent
oseltamivir
time
sampl
specimen
test
pcr
method
previous
identifi
infa
sampl
recognis
mtpcr
infa
assay
normalis
valu
rang
retriev
longterm
storag
templat
degrad
signific
possibl
six
could
assign
specif
haemagglutinin
subtyp
latter
normalis
infa
valu
three
known
infb
sampl
eight
rsvposit
sampl
correctli
identifi
mtpcr
normalis
valu
respect
data
shown
thu
mtpcr
recognis
known
posit
infa
sampl
previou
rtpcr
extract
result
origin
sampl
congruent
perform
tabl
howev
six
sixteen
sampl
report
neg
infa
posit
mtpcr
shown
six
one
also
weakli
posit
rtpcr
infa
report
neg
result
earlier
specimen
patient
posit
infa
anoth
four
case
addit
infa
detect
lowlevel
normalis
result
corrects
discret
secondstag
amplicon
determin
bioanalyz
agil
santaclara
ca
sigmoid
cycl
curv
singl
melt
peak
thought
repres
true
posit
result
sequenc
perform
six
unexpect
posit
confirm
result
test
posit
mtpcr
detect
signific
pathogen
inhous
rtpcr
previous
detect
greater
clinic
util
australian
influenza
season
replac
assay
assay
influenza
profil
infa
infb
rsv
rv
test
profil
independ
two
clinic
laboratori
cidm
imv
tabl
two
hundr
seventysix
clinic
specimen
test
cidm
test
mtpcr
congruent
result
obtain
ifposit
specimen
three
infa
specimen
detect
mtpcr
two
three
could
confirm
rtpcr
infa
either
suggest
falseposit
result
inhibit
detect
addit
specimen
neg
sampl
also
posit
mtpcr
infa
andor
one
infb
five
rsv
five
come
symptomat
patient
taken
investig
rsv
outbreak
addit
posit
mtpcr
result
lowlevel
normalis
unit
two
addit
ten
rsv
also
detect
sampl
test
infa
infb
includ
tabl
one
hundr
seventysix
addit
clinic
specimen
complet
unrel
test
test
rtpcr
imv
report
posit
mtpcr
result
congruent
tabl
neg
result
five
test
posit
mtpcr
profil
one
lowlevel
infa
four
rsv
rv
specimen
previous
test
pathogen
mtpcr
result
includ
tabl
infarsv
coinfect
alreadi
identifi
rtpcr
identifi
infa
coinfect
mtpcr
shown
quantit
natur
mtpcr
potenti
allow
comparison
normalis
valu
time
serial
infa
valu
alon
may
mislead
number
cell
sampl
measur
sampl
qualiti
vari
significantli
express
infa
valu
function
normalis
valu
human
nono
nonpou
domain
contain
octamerbind
gene
genbank
access
give
approxim
amount
human
epitheli
cell
harvest
sampl
infanono
ratio
deriv
small
subset
patient
assay
use
assay
influenza
profil
infa
infb
rsv
rv
nono
tabl
set
infanono
ratio
tabl
deriv
assay
serial
sampl
patient
treat
oseltamivir
influenza
cours
manag
institut
outbreak
demonstr
potenti
quantit
marker
sampl
qualiti
normalis
nono
valu
perhap
cours
infect
infanono
ratio
detect
method
avail
major
ili
pathogen
tabl
well
known
h
known
n
variant
antigenbas
rapid
assay
gener
quit
specif
rang
sensit
pcr
method
appear
sensit
specif
detect
limit
multiplex
pcr
must
deal
competit
interfer
aris
result
use
larg
number
primer
simultan
dna
hybridis
multiplex
pcr
one
solut
slow
labourintens
mtpcr
deal
problem
stop
multiplex
first
round
amplif
competit
develop
use
amplifi
product
templat
second
round
individu
specif
nest
reaction
evalu
control
variat
specimen
qualiti
oper
perform
number
variabl
applic
real
work
laboratori
use
autom
liquidhandl
system
robot
cycler
oper
preset
algorithm
cycl
call
result
result
manual
verifi
studi
requir
oper
expertis
otherwis
minim
secondstag
amplifi
product
seal
discard
unopen
everi
secondstep
gene
disc
well
target
assay
separ
spatial
addit
posit
describ
came
differ
day
neg
control
sever
neg
run
detect
mtpcr
reaction
yield
normal
melt
curv
reaction
give
unexpect
result
also
contain
discret
corrects
amplicon
multipl
unexpecteds
amplicon
discrep
melt
temperatur
identifi
nevertheless
sequenc
clinic
isol
perform
initi
test
valid
addit
altern
independ
test
perform
specif
verifi
secondstep
result
contamin
secondstep
reaction
unrel
firststep
amplicon
complet
exclud
mtpcr
method
essenti
nest
rtpcr
would
therefor
expect
sensit
convent
pcr
direct
antigen
detect
system
specif
may
thu
underestim
mtpcr
detect
target
sequenc
materi
level
detect
convent
method
test
control
templat
gave
clean
result
evid
crossreact
figur
unexpect
posit
result
obtain
neg
clinic
specimen
almost
uniformli
low
level
consist
explan
also
consist
unexpect
addit
posit
result
mtpcr
much
common
specimen
deem
neg
pcr
see
tabl
exampl
addit
mtpcrposit
ifneg
sampl
cidm
n
infa
collect
symptomat
patient
influenza
outbreak
sever
either
confirm
rtpcr
associ
seroconvers
greater
fourfold
increas
initi
high
titr
influenza
level
addit
posit
result
similar
seen
previou
report
assay
type
taken
togeth
includ
assay
test
within
profil
mtpcr
correctli
identifi
clinic
specimen
found
posit
standard
method
convers
take
account
specimen
found
posit
mtpcr
studi
detect
signific
pathogen
inhous
rtpcr
detect
influenza
detect
rel
sensit
rtpcr
compar
mtpcr
mtpcr
entir
congruent
clinic
specimen
test
infb
n
rsv
n
n
three
sampl
posit
neg
mtpcr
infa
one
could
confirm
repeat
test
falseposit
result
set
asid
mtpcr
sensit
rel
refer
laboratori
posit
result
would
recalcul
posit
result
obtain
cell
cultur
addit
control
tabl
includ
convers
detect
rtpcr
detect
mtpcr
posit
pathogen
includ
mani
addit
lowlevel
posit
infa
rel
sensit
overal
rel
mtpcr
inhous
rtpcr
human
influenza
viru
replic
throughout
respiratori
tract
viral
load
normal
peak
nasopharyng
sampl
hour
onset
symptom
determin
infecti
period
variabl
crucial
individu
public
health
plan
like
host
strainspecif
previou
test
rna
target
use
mtpcr
correl
quantit
two
log
templat
concentr
coeffici
variat
ten
independ
cycl
threshold
ct
measur
also
use
nono
marker
human
epitheli
cell
specimen
normalis
viral
titr
tabl
wellcollect
specimen
signific
amount
human
epitheli
cell
present
infanono
ratio
may
use
monitor
viral
shed
infect
howev
actual
primer
sequenc
may
fail
recognis
new
viral
variant
lack
transpar
manufactur
releas
inform
requir
evid
latest
sequenc
avail
complet
homolog
primer
includ
clinic
laboratori
trust
assay
given
readi
avail
influenza
sequenc
eg
via
pubm
reason
expect
minimum
standard
test
fullycharacteris
strain
includ
list
tabl
refer
sequenc
use
list
tabl
studi
isol
test
clinic
laboratori
came
two
australian
popul
centr
differ
region
may
encount
strain
significantli
differ
list
tabl
initi
target
consensu
clade
highli
pathogen
strain
consist
guidelin
http
region
target
consensu
infa
primer
vari
significantli
highli
pathogen
avian
strain
influenza
reflect
rel
low
sensit
infa
assay
sinc
assay
develop
also
experienc
influenza
pandem
caus
signific
number
intens
care
admiss
death
countri
requir
modif
includ
np
gene
gene
consensu
perform
australian
influenza
season
appear
compar
nest
rtpcr
specif
optimis
diagnosi
coinfect
eg
rsv
infa
caus
ili
may
clinic
import
pandem
influenza
dramat
increas
requir
highlevel
intens
care
abil
effici
distinguish
true
infa
ili
less
threaten
natur
context
outbreak
epidem
may
vital
minimis
burden
health
infrastructur
respiratori
syncyti
viru
rsv
singl
import
caus
acut
lower
respiratori
tract
diseas
includ
bronchiol
pneumonia
infant
young
children
may
contribut
hundr
thousand
death
annual
among
elderli
immunocompromis
human
parainfluenza
viru
type
associ
pharyng
bronchiol
pneumonia
children
respiratori
infect
adult
second
signific
acut
viral
respiratori
tract
infect
young
children
rsv
lead
caus
hospit
adult
acut
communityacquir
respiratori
diseas
rhinovirus
rv
serotyp
act
either
singl
pathogen
mix
infect
may
present
nonspecif
ili
test
sever
hundr
clinic
sampl
two
refer
laboratori
found
multiplex
tandem
mt
pcr
compar
targetspecif
rtpcr
great
deal
sensit
direct
immunofluoresc
detect
sever
import
caus
agent
influenzalik
ill
importantli
method
simultan
subtyp
influenza
identifi
multipl
pathogen
coinfect
singl
specimen
provid
potenti
valuabl
quantit
data
multiplex
method
also
facilit
recognit
cocircul
virus
outbreak
situat
might
otherwis
assum
ident
clear
influenza
vaccin
strategi
primer
design
need
review
regularli
light
preval
sequenc
variat
configur
multiplex
assay
need
inform
relev
epidemiolog
region
assay
describ
present
cost
around
aud
usd
target
usd
per
target
even
addit
purif
labour
cost
potenti
costeffect
routin
laboratori
ks
develop
patent
mtpcr
princip
ausdiagnost
commercialis
assay
es
employe
ausdiagnost
cours
research
es
kt
contribut
equal
paper
conduct
mtpcr
assay
sydney
prepar
raw
data
review
ks
dd
ji
km
kt
ta
perform
diagnost
assay
ta
perform
mtpcr
assay
adelaid
prepar
data
conjunct
gh
dd
gh
ji
advis
assay
configur
target
dd
obtain
crucial
control
sampl
ks
develop
target
primer
troubleshot
assay
es
supervis
initi
assay
develop
prior
clinic
valid
studi
ks
es
conduct
sever
diagnost
assay
run
initi
develop
stage
ji
conceiv
project
obtain
fund
oversaw
assay
cidm
conjunct
km
dd
analys
data
ks
wrote
paper
conjunct
ks
es
kt
dd
author
read
approv
final
manuscript
prepubl
histori
paper
access
http
